News

Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings (NASDAQ:APLS)

6 Mins read

Apellis Pharmaceuticals (NASDAQ:APLS), a standout player in the biotech sector, distinguishes itself with its novel C3 inhibitor technology, including their flagship compound, pegcetacoplan which has been branded into EMPAVELI (systemic) and SYVOVRE (intravitreal). Apellis has aimed pegcetacoplan to take on treating Paroxysmal Nocturnal Hemoglobinuria (PNH) and

Read the full article here

Related posts
News

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX)

1 Mins read
This article was written by Follow Background: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven…
News

Galiano Gold Inc. (GAU) Q2 2025 Earnings Call Transcript

1 Mins read
Galiano Gold Inc. (NYSE:GAU) Q2 2025 Earnings Conference Call August 14, 2025 10:30 AM ET Company Participants Matt Badylak – President, CEO…
News

Similarweb Ltd. 2025 Q2 - Results - Earnings Call Presentation (NYSE:SMWB)

1 Mins read
Q2: 2025-08-12 Earnings Summary EPS of $0.01 beats by $0.02  | Revenue of $70.97M (17.03% Y/Y) beats by $2.15M This article was written…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *